MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Striatonigral degeneration"

  • 2024 International Congress

    Dopamine Transporter Imaging as Monitoring Biomarker in Parkinson’s Disease

    V. Dzialas, G. Bischof, K. Möllenhoff, A. Drzezga, T. van Eimeren (Cologne, Germany)

    Objective: To investigate the longitudinal relationship between changes in dopamine transporter single-photon emission computed tomography (DaT SPECT) and changes in motor symptom severity in Parkinson’s…
  • 2024 International Congress

    Impact of Striatal Degeneration on Patient Reported Symptoms in Idiopathic Normal Pressure Hydrocephalus

    Q. Hu, K. Badiola-Lim, D. Karimeddini, C-L. Kuo, N. Prakash (Farmington, USA)

    Objective: To compare the subjective presenting motor (MS) and nonmotor symptoms (NMS) in subjects with idiopathic normal pressure hydrocephalus (iNPH) with and without striatal degeneration…
  • 2024 International Congress

    Impact of Striatal Degeneration on Clinical Phenotype in Idiopathic Normal Pressure Hydrocephalus: A Comparative Analysis

    K. Badiola-Lim, Q. Hu, N. Prakash (Summit, USA)

    Objective: To compare the clinical phenotype between patients with normal and abnormal dopamine transporter scan (DaTscan) in probable and definite idiopathic normal pressure hydrocephalus (iNPH).…
  • 2024 International Congress

    Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson’s Disease Model in Macaques

    M. Bradbury, M. Aumann, D. Claassen, D. Finkelstein (Newark, USA)

    Objective: (1) Determine whether oral ATH434 improves motor performance in a non-human primate hemiparkinasonian model when administered after symptom onset. (2) Relate observations to changes…
  • 2023 International Congress

    Automated VMAT2 [18F]AV-133 PET analysis in Parkinson’s disease

    R. Manber, B. Brito Vega, C. Mcginnity (London, United Kingdom)

    Objective: To evaluate a fully automated image analysis pipeline to process vesicular monoamine transporters type 2 (VMAT2) [18F]AV-133 tracer positron emission tomography (PET) images, by…
  • 2023 International Congress

    Blood NfL can track progression in multiple system atrophy

    V. Chelban, A. Perez-Soriano, C. Wilke, A. Foubert-Samier, N. Vijiaratnam, T. Guo, E. Jabbari, K. Senkevich, B. Laurens, P. Péran, O. Rascol, L. Schöls, C. Kobylecki, M. Hu, J. Rowe, T. Foltynie, N. Wood, A. Heslegrave, H. Zetterberg, M. Bocchetta, J. Rohrer, M. Marti, M. Synofzik, H. Morris, W. Meissner, H. Houlden (London, United Kingdom)

    Objective: To validate the role of NfL for disease progression, severity and subject trial selection in MSA. Neurofilament light (NfL) was explored in this regard though…
  • 2023 International Congress

    Network attack tolerance: A resilience proxy for Parkinson’s disease?

    A. Asendorf, A. Temizyürek, M. Banwinkler, V. Dzialas, THE. Parkinson-Progression-Marker-Initiative, T. van Eimeren, M. Hoenig (Cologne, Germany)

    Objective: To investigate if individual capacity in network attack tolerance moderates the relationship between striatal dopamine loss and symptom severity in PD. Background: It was…
  • 2022 International Congress

    Height and nigral neuron density in Parkinson’s disease

    L. Saari, E. Backman, P. Wahlsten, M. Gardberg, V. Kaasinen (Turku, Finland)

    Objective: To investigate the possible relationship between height and the density of neurons in the substantia nigra pars compacta (SNc). Background: The dopaminergic system modulates…
  • 2022 International Congress

    Gold and silver nanoparticle-based Localized Surface Plasmon Resonance Sensor (LSPR) for the detection of histidine as a potential biomarker in Parkinson’s Disease.

    E. Robles, C. Acevedo-Castillo, D. Martínez-Ramírez (Monterrey, Mexico)

    Objective: Previous literature has proven that histamine has a crucial role in the process of neuroinflammation in Parkinson's Disease (PD) . We can indirectly detect…
  • 2022 International Congress

    TRPV4 Mutation related Parkinson’s Disease with Scapuloperoneal spinal muscular atrophy

    A. Deenadayalu, P. A, V. Paramanandam (Limerick, Ireland)

    Objective: Scapuloperoneal spinal muscular atrophy (SPSMA) is a rare autosomal dominant disease caused by transient receptor potential cation channel (TRPV4) gene, involving scapular and peroneal…
  • 1
  • 2
  • 3
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25676 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley